financetom
Market
financetom
/
Market
/
Monday's top brokerage calls: Avenue Supermarts, Tech Mahindra and more
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Monday's top brokerage calls: Avenue Supermarts, Tech Mahindra and more
Jul 11, 2021 11:36 PM

Monday's top brokerage calls: Avenue Supermarts, Tech Mahindra and more

SUMMARY

Brokerages are mixed on Avenue Supermarts after its Q1 results. While Jefferies has an 'underperform call', Goldman Sachs has a 'buy' rating. Further CLSA is bullish on Tech Mahindra and Investec also has a 'buy' call on Equitas Holding. Here are the top brokerage calls for today.

By CNBCTV18.COMJul 12, 2021 8:39:08 AM IST (Updated)

Jefferies on Avenue Supermarts: The brokerage has an 'underperform' call on the stock with a target at Rs 2,300 per share. It said that it was surprised negatively with a 22-quarter low gross margin of 12.4 percent.

Goldman Sachs on Avenue Supermarts: The brokerage has a 'buy' call on the stock with a target at Rs 3,690 per share. However, it lowers FY22 EPS estimates by 7.9 percent to reflect a lower margin in Q1.

Citi on Avenue Supermarts: The brokerage has a 'sell' call on the stock with a target at Rs 2,210 per share. It cut estimates by another 8 percent for FY22.

CLSA on Tech Mahindra: The brokerage has a 'buy' call on the stock with a target at Rs 1,300 per share. It estimates restructuring legacy acquisitions to provide 70-80 bps margin leverage over the medium term for the firm.

Investec on Equitas Holding: The brokerage has a 'buy' call on the stock with a target at Rs 170 per share after the RBI approved SFBs to apply for a reverse merger.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Tech
Sector Update: Tech
Jul 9, 2025
01:15 PM EDT, 07/09/2025 (MT Newswires) -- Tech stocks were higher Wednesday afternoon, with the Technology Select Sector SPDR Fund (XLK) and the SPDR S&P Semiconductor ETF (XSD) each adding 0.2%. The Philadelphia Semiconductor index rose 0.4%. In corporate news, Microsoft's ( MSFT ) AI business potential is being underestimated by the market, according to Oppenheimer, which believes the tech...
US STOCKS-Wall Street shakes off tariff concerns, Nvidia leaps to $4 trillion
US STOCKS-Wall Street shakes off tariff concerns, Nvidia leaps to $4 trillion
Jul 9, 2025
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * Indexes up: Dow 0.06%, S&P 500 0.24%, Nasdaq 0.55% * Nvidia ( NVDA ) first company to hit $4 trillion market value * AES ( AES ) jumps on report of sale efforts * UnitedHealth ( UNH )...
Exchange-Traded Funds, US Equities Rise After Midday
Exchange-Traded Funds, US Equities Rise After Midday
Jul 9, 2025
01:09 PM EDT, 07/09/2025 (MT Newswires) -- Broad Market Indicators Broad-market exchange-traded funds IWM and IVV rose. Actively traded Invesco QQQ Trust (QQQ) was up 0.4%. US equity indexes rose with the Nasdaq Composite climbing to a record as Nvidia ( NVDA ) became the first company ever to surpass $4 trillion in market capitalization. Energy iShares US Energy ETF...
Update: Rhythm Pharmaceuticals Shares Surge After Bivamelagon Reduces BMI in Hypothalamic Obesity Trial
Update: Rhythm Pharmaceuticals Shares Surge After Bivamelagon Reduces BMI in Hypothalamic Obesity Trial
Jul 9, 2025
11:42 AM EDT, 07/09/2025 (MT Newswires) -- (Updates with the latest stock move in the headline and the first paragraph.) Rhythm Pharmaceuticals ( RYTM ) shares jumped nearly 33% in recent Wednesday trading after the company said bivamelagon achieved body mass index reductions in patients in its phase 2 acquired hypothalamic obesity trial. At 14 weeks of treatment, bivamelagon cut...
Copyright 2023-2026 - www.financetom.com All Rights Reserved